Page last updated: 2024-08-23

pirfenidone and pai 039

pirfenidone has been researched along with pai 039 in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Didiasova, M; Drakopanagiotakis, F; Krämer, M; Mamazhakypov, A; Markart, P; Schaefer, L; Wygrecka, M1

Other Studies

1 other study(ies) available for pirfenidone and pai 039

ArticleYear
Pirfenidone inhibits motility of NSCLC cells by interfering with the urokinase system.
    Cellular signalling, 2020, Volume: 65

    Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Humans; Indoleacetic Acids; Lung Neoplasms; Membrane Proteins; Plasminogen Activator Inhibitor 1; Pyridones; Tumor Microenvironment; Urokinase-Type Plasminogen Activator

2020